These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23660772)

  • 1. Methotrexate binds to recombinant thiopurine S-methyltransferase and inhibits enzyme activity after high-dose infusions in childhood leukaemia.
    Wennerstrand P; Mårtensson LG; Söderhäll S; Zimdahl A; Appell ML
    Eur J Clin Pharmacol; 2013 Sep; 69(9):1641-9. PubMed ID: 23660772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
    Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Importance of genotyping of thiopurine S-methyltransferase in children with acute lymphoblastic leukaemia during maintenance therapy].
    Dokmanović L; Janić D; Krstovski N; Zukić B; Tosić N; Pavlović S
    Srp Arh Celok Lek; 2008; 136(11-12):609-16. PubMed ID: 19177822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.
    Lennard L; Welch JC; Lilleyman JS
    Br J Clin Pharmacol; 1997 Nov; 44(5):455-61. PubMed ID: 9384462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Al-Modhwahi I; Andersen MK; Behrendtz M; Forestier E; Hasle H; Heyman M; Kristinsson J; Nersting J; Nygaard R; Svendsen AL; Vettenranta K; Weinshilboum R;
    Blood; 2009 Jun; 113(24):6077-84. PubMed ID: 19224761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
    Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
    J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency.
    Andersen JB; Szumlanski C; Weinshilboum RM; Schmiegelow K
    Acta Paediatr; 1998 Jan; 87(1):108-11. PubMed ID: 9510461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
    Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
    Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
    Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
    J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
    Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
    Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatotoxicity During Maintenance Therapy and Prognosis in Children With Acute Lymphoblastic Leukemia.
    Ebbesen MS; Nygaard U; Rosthøj S; Sørensen D; Nersting J; Vettenranta K; Wesenberg F; Kristinsson J; Harila-Saari A; Schmiegelow K
    J Pediatr Hematol Oncol; 2017 Apr; 39(3):161-166. PubMed ID: 28060115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
    Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
    Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Dreisig K; Brünner ED; Marquart HV; Helt LR; Nersting J; Frandsen TL; Jonsson OG; Taskinen M; Vaitkeviciene G; Lund B; Abrahamsson J; Lepik K; Schmiegelow K
    Pediatr Hematol Oncol; 2021 Apr; 38(3):227-238. PubMed ID: 33205673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
    Levinsen M; Rotevatn EØ; Rosthøj S; Nersting J; Abrahamsson J; Appell ML; Bergan S; Bechensteen AG; Harila-Saari A; Heyman M; Jonsson OG; Maxild JB; Niemi M; Söderhäll S; Schmiegelow K;
    Pediatr Blood Cancer; 2014 May; 61(5):797-802. PubMed ID: 24395436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia.
    Albayrak M; Konyssova U; Kaya Z; Gursel T; Guntekin S; Percin EF; Kocak U
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1155-9. PubMed ID: 21400026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of TPMT and ITPA variants in mercaptopurine disposition.
    Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiopurine S-methyltransferase phenotype-genotype correlation in children with acute lymphoblastic leukemia.
    Chrzanowska M; Kuehn M; Januszkiewicz-Lewandowska D; Kurzawski M; Droździk M
    Acta Pol Pharm; 2012; 69(3):405-10. PubMed ID: 22594254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
    Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
    Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Forestier E; Kristinsson J; Söderhäll S; Vettenranta K; Weinshilboum R; Wesenberg F;
    Leukemia; 2009 Mar; 23(3):557-64. PubMed ID: 18987654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.